We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
-2.95%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.13B
AUM Growth
-$333M
Cap. Flow
-$249M
Cap. Flow %
-22.11%
Top 10 Hldgs %
64.02%
Holding
82
New
15
Increased
14
Reduced
31
Closed
17

Top Buys

Rank Stock Value
1
HCA icon
HCA Healthcare
HCA
+$16.3M
2
BRKR icon
Bruker
BRKR
+$13.9M
3
TFX icon
Teleflex
TFX
+$12.7M
4
PCVX icon
Vaxcyte
PCVX
+$12.7M
5
EW icon
Edwards Lifesciences
EW
+$11.9M

Top Sells

Rank Stock Value
1
INSM icon
Insmed
INSM
+$79.5M
2
SNDX icon
Syndax Pharmaceuticals
SNDX
+$64.4M
3
UTHR icon
United Therapeutics
UTHR
+$32.1M
4
TECH icon
Bio-Techne
TECH
+$26.7M
5
CYH icon
Community Health Systems
CYH
+$25M

Sector Composition

Rank Sector Weight
1 Healthcare 86.03%
2 Miscellaneous 13.97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRUS
51
DELISTED
Merus
MRUS
$2.87M 0.25%
68,258
– –
MREO
52
Mereo BioPharma
MREO
$40.3M
$2.72M 0.24%
777,890
– –
ZLAB icon
53
Zai Lab
ZLAB
$2.93B
$2.7M 0.24%
102,930
-32,289
-24% -$896K
ARQT icon
54
Arcutis Biotherapeutics
ARQT
$2.99B
$2.66M 0.24%
191,158
-502,105
-72% -$5.5M
XRAY icon
55
Dentsply Sirona
XRAY
$2.22B
$2.65M 0.24%
+139,656
New +$2.95M
XOMA
56
DELISTED
Xoma
XOMA
$2.51M 0.22%
95,417
+1,128
+1% +$33K
ITOS
57
DELISTED
iTeos Therapeutics
ITOS
$1.69M 0.15%
+220,196
New +$1.89M
KPTI icon
58
Karyopharm Therapeutics
KPTI
$42.4M
$1.41M 0.13%
139,250
-230,609
-62% -$2.79M
ZBIO
59
Zenas BioPharma
ZBIO
$2.04B
$1.41M 0.13%
172,103
-18,428
-10% -$287K
STRO icon
60
Sutro Biopharma
STRO
$339M
$1.28M 0.11%
69,441
-114,758
-62% -$3.5M
IFRX icon
61
InflaRx
IFRX
$329M
$1.22M 0.11%
492,452
-1,129,335
-70% -$2.17M
AMRN
62
Amarin Corp
AMRN
$295M
$736K 0.07%
75,830
-89,635
-54% -$960K
ABSI icon
63
Absci
ABSI
$1.49B
$523K 0.05%
199,464
-73,405
-27% -$258K
ALEC icon
64
Alector
ALEC
$261M
$378K 0.03%
200,095
-132,661
-40% -$499K
AUTL
65
Autolus Therapeutics
AUTL
$623M
$232K 0.02%
98,895
-307,663
-76% -$1.04M
ACIU icon
66
AC Immune
ACIU
$263M
– –
-99,313
Closed -$375K
AFMD
67
DELISTED
Affimed
AFMD
– –
-166,460
Closed -$559K
JBIO
68
Jade Biosciences
JBIO
$1.33B
– –
-13,861
Closed -$1.01M
BHC icon
69
Bausch Health
BHC
$2.36B
– –
-1,530,914
Closed -$12.5M
BHVN icon
70
Biohaven
BHVN
$2.33B
– –
-132,537
Closed -$6.62M
BKD icon
71
Brookdale Senior Living
BKD
$2.8B
– –
-861,268
Closed -$5.85M
INSM icon
72
Insmed
INSM
$25.9B
– –
-1,089,404
Closed -$79.5M
IQV icon
73
IQVIA
IQV
$43.1B
– –
-13,138
Closed -$3.11M
KURA icon
74
Kura Oncology
KURA
$1.13B
– –
-192,398
Closed -$3.76M
MOH icon
75
Molina Healthcare
MOH
$10.4B
– –
-10,588
Closed -$3.65M
1 2
3
4

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q4 2024 Portfolio in Review

As of Q4 2024, Eversept Partners held 82 positions worth $1.13B, down 23% from $1.46B the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Eversept Partners withdrew a net $249M in Q4 2024, closing 17 positions and reducing 31 holdings. Its most notable exit was Insmed, an estimated $79.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 89% a quarter earlier, followed by Miscellaneous.

Against the trend, Eversept Partners opened a new position in Bruker worth $13.8M.

  • Eversept Partners's largest Q4 2024 buy was Bruker: 234,934 shares worth $13.8M.
  • Eversept Partners added most to HCA Healthcare in Q4 2024, an estimated $16.3M increase.
  • Eversept Partners's biggest Q4 2024 reduction was Syndax Pharmaceuticals, cutting an estimated $64.4M.
  • Eversept Partners fully exited Insmed in Q4 2024, selling an estimated $79.5M.
  • Eversept Partners's ten largest holdings make up 64% of its $1.13B portfolio in Q4 2024.
  • Eversept Partners opened 15 new positions and closed 17 in Q4 2024.
  • Eversept Partners's portfolio value fell 23% quarter-over-quarter to $1.13B.

Based on Eversept Partners's 13F filing for Q4 2024, filed 14 Feb 2025.